Clinical Trials » Macular Degeneration
Cell-Based Treatment for Dry AMD: Advanced Cell Technology (ACT)
|
RECRUITING Description: ACT has launched a Phase I/II clinical trial of transplanted retinal pigment epithelial (RPE) cells for the treatment of dry age-related macular degeneration. The RPE cells are derived from human stem cells. RPE are the first cells affected in people with dry AMD. They play a critical role in maintaining the health and function of photoreceptors. The study, taking place at the Jules Stein Eye Institute at the University of California, Los Angeles, will enroll up to 12 participants. The Foundation funded many of the preclinical studies that made this human trial possible. Trial status: Recruiting participants. Partial List of Participation Criteria:
Logan Hitchcock (310) 825-3046 Jules Stein Eye Institute, UCLA Los Angeles, CA Bascom Palmer Eye Institute Miami, Florida Contact: Cristy M Lage-Rodriguez, M.S., C.C.R.C 305-326-6117 This e-mail address is being protected from spambots. You need JavaScript enabled to view it Wills Eye Institute-Mid Atlantic Retina Philadelphia, Pennsylvania Contact: Shellie Markun This e-mail address is being protected from spambots. You need JavaScript enabled to view it Articles: Clinical Trials Underway for Stem Cell Treatments Additional Information: ACT stem cell clinical trial for dry AMD listing on ClinicalTrials.gov |
